Barclays’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-6,969
| Closed | -$14K | – | 4973 |
|
|
2021
Q3 | $14K | Sell |
6,969
-42,870
| -86% | -$99.8K | ﹤0.01% | 4477 |
|
|
2021
Q2 | $148K | Buy |
49,839
+13,032
| +35% | +$34.4K | ﹤0.01% | 3679 |
|
|
2021
Q1 | $102K | Buy |
36,807
+22,595
| +159% | +$68.2K | ﹤0.01% | 4002 |
|
|
2020
Q4 | $34K | Sell |
14,212
-2,266
| -14% | -$5.46K | ﹤0.01% | 4562 |
|
|
2020
Q3 | $35K | Sell |
16,478
-3,319
| -17% | -$11.2K | ﹤0.01% | 4754 |
|
|
2020
Q2 | $74K | Buy |
19,797
+7,796
| +65% | +$23.4K | ﹤0.01% | 4716 |
|
|
2020
Q1 | $23K | Sell |
12,001
-25,076
| -68% | -$65.2K | ﹤0.01% | 5607 |
|
|
2019
Q4 | $77K | Buy |
37,077
+17,718
| +92% | +$34K | ﹤0.01% | 5601 |
|
|
2019
Q3 | $46K | Sell |
19,359
-15,160
| -44% | -$40.7K | ﹤0.01% | 5951 |
|
|
2019
Q2 | $108K | Buy |
34,519
+10,413
| +43% | +$38.2K | ﹤0.01% | 5636 |
|
|
2019
Q1 | $120K | Buy |
24,106
+23,900
| +11,602% | +$118K | ﹤0.01% | 5218 |
|
|
2018
Q4 | $1K | Sell |
206
-72,034
| -100% | -$352K | ﹤0.01% | 6861 |
|
|
2018
Q3 | $350K | Buy |
72,240
+16,469
| +30% | +$84.3K | ﹤0.01% | 4565 |
|
|
2018
Q2 | $335K | Buy |
55,771
+34,662
| +164% | +$254K | ﹤0.01% | 4296 |
|
|
2018
Q1 | $188K | Buy |
21,109
+17,125
| +430% | +$128K | ﹤0.01% | 4875 |
|
|
2017
Q4 | $28K | Buy |
3,984
+3,446
| +641% | +$21.5K | ﹤0.01% | 6125 |
|
|
2017
Q3 | $4K | Buy |
538
+521
| +3,065% | +$3.6K | ﹤0.01% | 6537 |
|
|
2017
Q2 | $0 | Sell |
17
-15,297
| -100% | -$70.7K | ﹤0.01% | 7074 |
|
|
2017
Q1 | $73K | Buy |
+15,314
| New | +$46.9K | ﹤0.01% | 5106 |
|
Barclays's SBBP Position: Q4 2021 in Review
Barclays sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 6,969 shares — an estimated $14K sold.
Barclays first reported a position in SBBP in Q1 2017 and held it in 19 quarters. The position peaked at $350K in Q3 2018. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Barclays reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Barclays sold 6,969 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $14K.
- Barclays first reported a position in Strongbridge Biopharma plc. in Q1 2017 and held it in 19 quarters.
- Barclays's Strongbridge Biopharma plc. position peaked at $350K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.